within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK09_FormoterolAndMometasone;
model FormoterolAndMometasone 
   extends Pharmacolibrary.Drugs.ATC.R.R03AK09;

  annotation(Documentation(
    info ="<html><body><p>Formoterol and mometasone is a fixed-dose combination inhalation medication consisting of formoterol, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, an inhaled corticosteroid (ICS). This combination is approved and widely used today for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for formoterol and mometasone based on typical inhaled dosing in healthy adults; no specific published population PK study available for the fixed combination product. Individual PK parameters are derived from population means reported for each drug as single agent administered by inhalation.</p><h4>References</h4><ol><li><p> (2020). Drugs for COPD. <i>The Medical letter on drugs and therapeutics</i> 62(1606) 137–144. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32960872/&quot;>https://pubmed.ncbi.nlm.nih.gov/32960872</a></p></li><li><p>Tashkin, DP, et al., &amp; Staudinger, H (2012). Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. <i>International journal of chronic obstructive pulmonary disease</i> 7 73–86. DOI:<a href=&quot;https://doi.org/10.2147/COPD.S29444&quot;>10.2147/COPD.S29444</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22334770/&quot;>https://pubmed.ncbi.nlm.nih.gov/22334770</a></p></li><li><p>Kosoglou, T, et al., &amp; Cutler, DL (2014). Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device. <i>Clinical pharmacology in drug development</i> 3(3) 222–228. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.94&quot;>10.1002/cpdd.94</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27128612/&quot;>https://pubmed.ncbi.nlm.nih.gov/27128612</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end FormoterolAndMometasone;
